|
KMID : 0931320170170040179
|
|
대한상부위장관.헬리코박터학회지
2017 Volume.17 No. 4 p.179 ~ p.184
|
|
|
Chemoprevention of Gastric Cancer: Metformin
|
|
Kim Young-Il
Cho Soo-Jeong
|
|
|
Abstract
|
|
|
|
Metformin is a first-line anti-diabetic drug that has been widely used in patients with type 2 diabetes. Many population-based epidemiologic studies have shown that metformin treatment is associated with decreased risk for various cancers. Recent epidemiologic studies showed that the use of metformin was associated with a reduction in gastric cancer risk, especially in patients with type 2 diabetes who used metformin for long periods of time (>2∼3 years). Currently, there are no registered clinical trials investigating the anti-cancer effect of metformin in gastric cancer; hence, further well-designed clinical trials are required. Herein, we review the literature regarding the use of metformin for the prevention of gastric cancer.
|
|
|
KEYWORD
|
|
|
Chemoprevention, Metformin, Stomach neoplasms
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
  
|